JPWO2021240369A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021240369A5 JPWO2021240369A5 JP2022573217A JP2022573217A JPWO2021240369A5 JP WO2021240369 A5 JPWO2021240369 A5 JP WO2021240369A5 JP 2022573217 A JP2022573217 A JP 2022573217A JP 2022573217 A JP2022573217 A JP 2022573217A JP WO2021240369 A5 JPWO2021240369 A5 JP WO2021240369A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- use according
- dmard
- seq
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 12
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 10
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 5
- 229960000485 methotrexate Drugs 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 239000004012 Tofacitinib Substances 0.000 claims 2
- 229940125644 antibody drug Drugs 0.000 claims 2
- 229950000971 baricitinib Drugs 0.000 claims 2
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims 2
- 230000009266 disease activity Effects 0.000 claims 2
- 102000052611 human IL6 Human genes 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229950006348 sarilumab Drugs 0.000 claims 2
- 229960001350 tofacitinib Drugs 0.000 claims 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims 2
- 229950000088 upadacitinib Drugs 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030065P | 2020-05-26 | 2020-05-26 | |
| US63/030,065 | 2020-05-26 | ||
| US202163155125P | 2021-03-01 | 2021-03-01 | |
| US63/155,125 | 2021-03-01 | ||
| EP21315087.3 | 2021-05-25 | ||
| EP21315087 | 2021-05-25 | ||
| PCT/IB2021/054546 WO2021240369A1 (en) | 2020-05-26 | 2021-05-25 | Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023527059A JP2023527059A (ja) | 2023-06-26 |
| JPWO2021240369A5 true JPWO2021240369A5 (https=) | 2024-06-03 |
| JP2023527059A5 JP2023527059A5 (https=) | 2024-06-03 |
Family
ID=76197513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573217A Pending JP2023527059A (ja) | 2020-05-26 | 2021-05-25 | 関節リウマチを治療するためのインターロイキン６受容体に対する抗体を含む組成物およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230174657A1 (https=) |
| JP (1) | JP2023527059A (https=) |
| AU (1) | AU2021281119A1 (https=) |
| BR (1) | BR112022024020A2 (https=) |
| CA (1) | CA3180369A1 (https=) |
| IL (1) | IL298088A (https=) |
| WO (1) | WO2021240369A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020261431A1 (en) | 2019-04-24 | 2021-12-09 | Regeneron Pharmaceuticals, Inc. | Methods of diagnosis and treatment of rheumatoid arthritis |
| EP3980459A1 (en) | 2019-06-04 | 2022-04-13 | Sanofi Biotechnology | Compositions and methods for treating pain in subj ects with rheumatoid arthritis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US8080248B2 (en) * | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
| US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
| US20140155827A1 (en) | 2012-12-03 | 2014-06-05 | Mylan, Inc. | Medicament information system and method |
| AU2019329958B2 (en) * | 2018-08-29 | 2025-05-29 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating subjects having rheumatoid arthritis |
-
2021
- 2021-05-25 IL IL298088A patent/IL298088A/en unknown
- 2021-05-25 CA CA3180369A patent/CA3180369A1/en active Pending
- 2021-05-25 BR BR112022024020A patent/BR112022024020A2/pt unknown
- 2021-05-25 WO PCT/IB2021/054546 patent/WO2021240369A1/en not_active Ceased
- 2021-05-25 US US17/926,018 patent/US20230174657A1/en active Pending
- 2021-05-25 JP JP2022573217A patent/JP2023527059A/ja active Pending
- 2021-05-25 AU AU2021281119A patent/AU2021281119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024069453A5 (https=) | ||
| US20240417455A1 (en) | Treatment for rheumatoid arthritis | |
| JP2025172841A5 (https=) | ||
| AU2012312225B2 (en) | Cachexia treatment | |
| AU2011293554B2 (en) | Treatment for neoplastic diseases | |
| JP2018515493A5 (https=) | ||
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| JP2022502350A5 (https=) | ||
| JP2022523530A (ja) | 化膿性汗腺炎の治療のための抗ＩＬ－α抗体 | |
| JP2024069230A5 (https=) | ||
| CN114375306A (zh) | 奥法木单抗治疗患者中除多发性硬化症以外病症的管理 | |
| JP2025072440A5 (https=) | ||
| JPWO2021240369A5 (https=) | ||
| JP2019535716A5 (https=) | ||
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| CA3176673A1 (en) | Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease | |
| JPWO2020047029A5 (https=) | ||
| JPWO2020247461A5 (https=) | ||
| JP7132256B2 (ja) | 関節リウマチの治療 | |
| WO2025257781A1 (en) | Treatment of systemic sclerosis using anti-baff-r antibodies | |
| JPWO2020033872A5 (https=) | ||
| WO2024077113A1 (en) | Methods of treating fatigue in ulcerative colitis | |
| WO2025181224A1 (en) | Cd19-selective t cell engaging molecule for treating autoimmune diseases/ autoimmune conditions | |
| JP2024516019A (ja) | 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療 | |
| JPWO2020128864A5 (https=) |